Genmab Phase 3 Trial Shows Positive Results for Head and Neck Cancer Combo

Genmab announced positive phase 3 results for petosemtamab combined with another drug in head and neck cancer. The data likely supports regulatory submission, but details on magnitude and statistical significance remain undisclosed. This is a company-specific clinical milestone with no immediate macro-market implications.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works